Literature DB >> 25705904

CYP3A4-mediated pharmacokinetic interactions in cancer therapy.

Dandan Tian, Zheyi Hu1.   

Abstract

Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25705904     DOI： 10.2174/1389200216666150223152627

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN： 1389-2002            Impact factor:   3.731


  10 in total

Review 1.  Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Authors:  Gera Narendra; Shalki Choudhary; Baddipadige Raju; Himanshu Verma; Om Silakari
Journal:  Clin Pharmacokinet       Date:  2022-09-30       Impact factor: 5.577

2.  Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Jeffrey Z Nie; Yuanqin Zhang; Daotai Nie
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-15       Impact factor: 3.333

3.  Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.

Authors:  Meghan M Cromie; Weimin Gao
Journal:  Oxid Med Cell Longev       Date:  2015-04-01       Impact factor: 6.543

Review 4.  Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.

Authors:  Ariane R Guthrie; H-H Sherry Chow; Jessica A Martinez
Journal:  Pharmacol Res Perspect       Date:  2017-01-31

Review 5.  Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions.

Authors:  Feng Chen; Li Li; Dan-Dan Tian
Journal:  Biomed Res Int       Date:  2017-04-03       Impact factor: 3.411

6.  The Chinese herb Styrax triggers pharmacokinetic herb-drug interactions via inhibiting intestinal CYP3A.

Authors:  Feng Zhang; Tiantian Zhang; Jiahao Gong; Qinqin Fang; Shenglan Qi; Mengting Li; Yan Han; Wei Liu; Guangbo Ge
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

Review 7.  Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?

Authors:  Dirk Theile; Pauline Wizgall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-08       Impact factor: 3.000

8.  Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs' Cytotoxicity, Metabolism and Cellular Response.

Authors:  Monika Pawłowska; Anna Kwaśniewska; Zofia Mazerska; Ewa Augustin
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

Review 9.  Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.

Authors:  Gabriel Gazzé
Journal:  Melanoma Manag       Date:  2018-06-19

Review 10.  Drug-Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms.

Authors:  Érique José F Peixoto de Miranda; Thamy Takahashi; Felipe Iwamoto; Suzete Yamashiro; Eliana Samano; Ariane Vieira Scarlatelli Macedo; Eduardo Ramacciotti
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.